 Robert McQueen
Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 31 | 2026 | 634 | 3.620 |
Why?
| | Drug Costs | 7 | 2025 | 116 | 2.160 |
Why?
| | Negotiating | 4 | 2025 | 34 | 1.870 |
Why?
| | Quality-Adjusted Life Years | 12 | 2024 | 121 | 1.700 |
Why?
| | Diabetes Mellitus, Type 1 | 11 | 2026 | 3890 | 1.520 |
Why?
| | Medicare | 4 | 2025 | 886 | 1.380 |
Why?
| | Models, Economic | 8 | 2025 | 62 | 1.290 |
Why?
| | Blood Glucose Self-Monitoring | 5 | 2026 | 699 | 1.240 |
Why?
| | Patient-Centered Care | 3 | 2025 | 544 | 1.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 8 | 2026 | 985 | 1.170 |
Why?
| | Health Expenditures | 3 | 2024 | 194 | 1.000 |
Why?
| | Genetic Therapy | 3 | 2025 | 313 | 0.950 |
Why?
| | Natalizumab | 4 | 2015 | 41 | 0.930 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2015 | 82 | 0.920 |
Why?
| | Drug Industry | 1 | 2025 | 49 | 0.910 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 439 | 0.910 |
Why?
| | Financing, Government | 1 | 2025 | 53 | 0.900 |
Why?
| | Research Support as Topic | 1 | 2025 | 80 | 0.900 |
Why?
| | Technology Assessment, Biomedical | 3 | 2022 | 44 | 0.890 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2025 | 140 | 0.880 |
Why?
| | Reimbursement Mechanisms | 1 | 2025 | 80 | 0.840 |
Why?
| | Immunologic Factors | 3 | 2015 | 255 | 0.830 |
Why?
| | Decision Support Techniques | 4 | 2022 | 456 | 0.820 |
Why?
| | Asthma | 6 | 2023 | 1767 | 0.810 |
Why?
| | Ovarian Neoplasms | 2 | 2020 | 586 | 0.810 |
Why?
| | Medicaid | 2 | 2025 | 461 | 0.800 |
Why?
| | Diabetic Retinopathy | 1 | 2026 | 208 | 0.790 |
Why?
| | Hemophilia B | 1 | 2023 | 66 | 0.770 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 199 | 0.760 |
Why?
| | Azetidines | 1 | 2022 | 45 | 0.750 |
Why?
| | United States | 20 | 2025 | 15966 | 0.740 |
Why?
| | Endometriosis | 1 | 2023 | 57 | 0.730 |
Why?
| | Hypercholesterolemia | 1 | 2022 | 92 | 0.710 |
Why?
| | Hemophilia A | 1 | 2023 | 147 | 0.690 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2024 | 2583 | 0.670 |
Why?
| | Anticholesteremic Agents | 1 | 2022 | 152 | 0.660 |
Why?
| | Anemia, Sickle Cell | 1 | 2025 | 312 | 0.650 |
Why?
| | Value-Based Purchasing | 1 | 2019 | 8 | 0.620 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2026 | 1180 | 0.600 |
Why?
| | Academies and Institutes | 1 | 2019 | 60 | 0.600 |
Why?
| | Humans | 63 | 2026 | 144759 | 0.590 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 132 | 0.570 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 134 | 0.570 |
Why?
| | Atherosclerosis | 1 | 2022 | 409 | 0.570 |
Why?
| | Hypoglycemic Agents | 3 | 2024 | 1387 | 0.560 |
Why?
| | Biological Therapy | 1 | 2018 | 28 | 0.560 |
Why?
| | Health Care Costs | 2 | 2020 | 427 | 0.550 |
Why?
| | Blood Glucose | 5 | 2026 | 2327 | 0.540 |
Why?
| | Foodborne Diseases | 3 | 2024 | 61 | 0.530 |
Why?
| | Telephone | 1 | 2018 | 175 | 0.510 |
Why?
| | Mass Screening | 3 | 2026 | 1347 | 0.500 |
Why?
| | Health Benefit Plans, Employee | 1 | 2015 | 26 | 0.460 |
Why?
| | Lung Neoplasms | 2 | 2026 | 2637 | 0.450 |
Why?
| | Research Design | 4 | 2024 | 1135 | 0.430 |
Why?
| | Anti-Asthmatic Agents | 4 | 2018 | 251 | 0.410 |
Why?
| | Insulin | 1 | 2024 | 2507 | 0.390 |
Why?
| | Hypoglycemia | 2 | 2024 | 477 | 0.390 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 2168 | 0.380 |
Why?
| | Markov Chains | 4 | 2025 | 129 | 0.380 |
Why?
| | Female | 27 | 2026 | 78271 | 0.370 |
Why?
| | Drug Monitoring | 1 | 2015 | 395 | 0.360 |
Why?
| | Metformin | 1 | 2015 | 318 | 0.360 |
Why?
| | Immunotherapy, Adoptive | 3 | 2019 | 337 | 0.340 |
Why?
| | Insurance Claim Review | 2 | 2024 | 83 | 0.330 |
Why?
| | Cost of Illness | 4 | 2024 | 321 | 0.330 |
Why?
| | Medication Adherence | 1 | 2015 | 539 | 0.320 |
Why?
| | Costs and Cost Analysis | 3 | 2020 | 219 | 0.320 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2925 | 0.320 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 653 | 0.320 |
Why?
| | Male | 23 | 2026 | 72315 | 0.310 |
Why?
| | Middle Aged | 18 | 2026 | 35875 | 0.280 |
Why?
| | Adolescent | 13 | 2026 | 22428 | 0.270 |
Why?
| | Diabetes Mellitus | 1 | 2017 | 1098 | 0.270 |
Why?
| | Young Adult | 12 | 2026 | 14105 | 0.270 |
Why?
| | Adult | 18 | 2026 | 40449 | 0.270 |
Why?
| | Neoplasms | 2 | 2020 | 2875 | 0.270 |
Why?
| | Autoantibodies | 3 | 2026 | 1501 | 0.260 |
Why?
| | Aged | 11 | 2026 | 25913 | 0.250 |
Why?
| | Retrospective Studies | 11 | 2026 | 17066 | 0.240 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 1047 | 0.240 |
Why?
| | Comparative Effectiveness Research | 2 | 2025 | 170 | 0.230 |
Why?
| | Colorado | 4 | 2025 | 4564 | 0.230 |
Why?
| | Health Priorities | 1 | 2025 | 42 | 0.230 |
Why?
| | Public-Private Sector Partnerships | 1 | 2025 | 44 | 0.230 |
Why?
| | Multimorbidity | 1 | 2025 | 63 | 0.220 |
Why?
| | Omalizumab | 2 | 2023 | 43 | 0.210 |
Why?
| | Syphilis | 1 | 2024 | 33 | 0.210 |
Why?
| | Heterocyclic Compounds, 2-Ring | 1 | 2023 | 18 | 0.200 |
Why?
| | Thiadiazoles | 1 | 2023 | 27 | 0.190 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2023 | 8 | 0.190 |
Why?
| | Dicarboxylic Acids | 1 | 2022 | 10 | 0.190 |
Why?
| | Ezetimibe | 1 | 2022 | 24 | 0.190 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 121 | 0.190 |
Why?
| | Stakeholder Participation | 1 | 2023 | 84 | 0.190 |
Why?
| | Insurance Coverage | 1 | 2024 | 239 | 0.190 |
Why?
| | Follow-Up Studies | 2 | 2026 | 5408 | 0.180 |
Why?
| | Diabetic Ketoacidosis | 2 | 2026 | 210 | 0.180 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 760 | 0.180 |
Why?
| | Insurance, Health | 1 | 2024 | 302 | 0.180 |
Why?
| | Decision Making | 4 | 2019 | 975 | 0.170 |
Why?
| | Incidence | 2 | 2026 | 2879 | 0.170 |
Why?
| | Food Microbiology | 1 | 2021 | 73 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 170 | 0.160 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 358 | 0.160 |
Why?
| | Models, Econometric | 2 | 2018 | 34 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2020 | 1720 | 0.160 |
Why?
| | Treatment Outcome | 9 | 2022 | 11679 | 0.160 |
Why?
| | Eicosapentaenoic Acid | 1 | 2020 | 36 | 0.160 |
Why?
| | Patient Participation | 1 | 2024 | 431 | 0.160 |
Why?
| | Fees, Medical | 1 | 2019 | 9 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2947 | 0.150 |
Why?
| | Perception | 1 | 2022 | 377 | 0.150 |
Why?
| | Fatty Acids | 1 | 2022 | 450 | 0.150 |
Why?
| | Teicoplanin | 1 | 2019 | 14 | 0.150 |
Why?
| | Pyrimidines | 1 | 2023 | 532 | 0.150 |
Why?
| | Indazoles | 1 | 2019 | 80 | 0.140 |
Why?
| | Early Diagnosis | 1 | 2020 | 249 | 0.140 |
Why?
| | Phthalazines | 1 | 2019 | 64 | 0.140 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 69 | 0.140 |
Why?
| | Computer Simulation | 2 | 2026 | 1025 | 0.140 |
Why?
| | Antigens, CD19 | 1 | 2019 | 129 | 0.140 |
Why?
| | Case-Control Studies | 1 | 2026 | 3604 | 0.140 |
Why?
| | Disease Progression | 1 | 2026 | 2847 | 0.140 |
Why?
| | England | 1 | 2018 | 111 | 0.140 |
Why?
| | Open Access Publishing | 1 | 2017 | 6 | 0.140 |
Why?
| | Rivaroxaban | 1 | 2020 | 267 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2025 | 8265 | 0.130 |
Why?
| | Lymphoma, B-Cell | 1 | 2019 | 132 | 0.130 |
Why?
| | Piperidines | 1 | 2019 | 217 | 0.130 |
Why?
| | Data Collection | 1 | 2020 | 633 | 0.130 |
Why?
| | Dry Powder Inhalers | 1 | 2017 | 1 | 0.130 |
Why?
| | Peer Review, Research | 1 | 2017 | 36 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 244 | 0.130 |
Why?
| | Metered Dose Inhalers | 1 | 2017 | 8 | 0.130 |
Why?
| | Parkinson Disease | 1 | 2024 | 600 | 0.130 |
Why?
| | Time Factors | 2 | 2026 | 7173 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2194 | 0.130 |
Why?
| | Aspirin | 1 | 2020 | 399 | 0.130 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.120 |
Why?
| | Piperazines | 1 | 2019 | 381 | 0.120 |
Why?
| | Hospitalization | 4 | 2024 | 2433 | 0.120 |
Why?
| | Economics, Pharmaceutical | 1 | 2016 | 10 | 0.120 |
Why?
| | Medication Errors | 1 | 2017 | 83 | 0.120 |
Why?
| | Child, Preschool | 4 | 2026 | 11787 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 681 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 640 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2020 | 1095 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2018 | 161 | 0.120 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 304 | 0.120 |
Why?
| | Child | 7 | 2026 | 22633 | 0.120 |
Why?
| | Spirometry | 1 | 2016 | 231 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 293 | 0.110 |
Why?
| | Information Dissemination | 1 | 2017 | 223 | 0.110 |
Why?
| | Quality of Life | 3 | 2024 | 3185 | 0.110 |
Why?
| | Indoles | 1 | 2019 | 501 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2021 | 621 | 0.110 |
Why?
| | Primary Health Care | 1 | 2025 | 1733 | 0.110 |
Why?
| | Intellectual Property | 3 | 2019 | 7 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 324 | 0.110 |
Why?
| | Telemedicine | 1 | 2024 | 945 | 0.100 |
Why?
| | Eosinophils | 1 | 2016 | 316 | 0.100 |
Why?
| | Canada | 1 | 2015 | 428 | 0.100 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2014 | 51 | 0.100 |
Why?
| | Anticoagulants | 1 | 2019 | 722 | 0.100 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 129 | 0.100 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2014 | 133 | 0.100 |
Why?
| | Sex Factors | 2 | 2017 | 2112 | 0.100 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2019 | 947 | 0.090 |
Why?
| | Fasting | 1 | 2014 | 277 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1326 | 0.090 |
Why?
| | Ergocalciferols | 1 | 2012 | 14 | 0.090 |
Why?
| | Diabetes Complications | 1 | 2014 | 222 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2014 | 1306 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3333 | 0.090 |
Why?
| | Comorbidity | 2 | 2014 | 1658 | 0.090 |
Why?
| | Income | 1 | 2012 | 202 | 0.090 |
Why?
| | International Classification of Diseases | 2 | 2022 | 147 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2019 | 668 | 0.080 |
Why?
| | Unemployment | 1 | 2010 | 42 | 0.080 |
Why?
| | Prescription Drugs | 1 | 2012 | 111 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2014 | 318 | 0.080 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 108 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 186 | 0.080 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1169 | 0.080 |
Why?
| | Databases, Factual | 1 | 2015 | 1486 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 2027 | 0.070 |
Why?
| | Infant | 3 | 2026 | 10034 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1907 | 0.070 |
Why?
| | Vitamin D | 1 | 2012 | 400 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 846 | 0.070 |
Why?
| | Epilepsy | 1 | 2012 | 376 | 0.070 |
Why?
| | Depressive Disorder | 1 | 2010 | 387 | 0.070 |
Why?
| | Uncertainty | 2 | 2019 | 144 | 0.060 |
Why?
| | Chronic Disease | 2 | 2025 | 1813 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2011 | 484 | 0.060 |
Why?
| | Cohort Studies | 4 | 2019 | 5960 | 0.060 |
Why?
| | Cost Savings | 1 | 2024 | 86 | 0.050 |
Why?
| | Hemorrhage | 2 | 2020 | 809 | 0.050 |
Why?
| | C-Peptide | 1 | 2025 | 189 | 0.050 |
Why?
| | Demography | 1 | 2024 | 288 | 0.050 |
Why?
| | Neurologists | 1 | 2024 | 22 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 488 | 0.050 |
Why?
| | Sexual Partners | 1 | 2024 | 192 | 0.050 |
Why?
| | Recurrence | 2 | 2018 | 1135 | 0.050 |
Why?
| | Glatiramer Acetate | 2 | 2013 | 18 | 0.050 |
Why?
| | Stress, Psychological | 1 | 2010 | 1152 | 0.040 |
Why?
| | Pregnancy | 2 | 2024 | 7190 | 0.040 |
Why?
| | Massachusetts | 1 | 2022 | 180 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 279 | 0.040 |
Why?
| | Risk Factors | 3 | 2024 | 10779 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 320 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 77 | 0.040 |
Why?
| | Off-Label Use | 1 | 2019 | 49 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2019 | 47 | 0.040 |
Why?
| | Vancomycin | 1 | 2019 | 93 | 0.040 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 89 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 105 | 0.030 |
Why?
| | Population Surveillance | 1 | 2021 | 485 | 0.030 |
Why?
| | Algorithms | 1 | 2026 | 1837 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 89 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2019 | 205 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 194 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 244 | 0.030 |
Why?
| | Asia | 1 | 2016 | 70 | 0.030 |
Why?
| | Peptides | 2 | 2013 | 995 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 221 | 0.030 |
Why?
| | Medicine | 1 | 2017 | 125 | 0.030 |
Why?
| | Policy Making | 1 | 2016 | 82 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2017 | 574 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1382 | 0.030 |
Why?
| | Biological Products | 1 | 2019 | 252 | 0.030 |
Why?
| | Palliative Care | 1 | 2024 | 1002 | 0.030 |
Why?
| | HIV Infections | 2 | 2024 | 3154 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 730 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2014 | 155 | 0.030 |
Why?
| | Cystatin C | 1 | 2014 | 65 | 0.030 |
Why?
| | Probability | 1 | 2014 | 310 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 478 | 0.020 |
Why?
| | Length of Stay | 1 | 2019 | 1337 | 0.020 |
Why?
| | Propylene Glycols | 1 | 2013 | 27 | 0.020 |
Why?
| | Sphingosine | 1 | 2013 | 45 | 0.020 |
Why?
| | Fingolimod Hydrochloride | 1 | 2013 | 39 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2024 | 6429 | 0.020 |
Why?
| | Health Policy | 1 | 2016 | 400 | 0.020 |
Why?
| | Vascular Calcification | 1 | 2014 | 110 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2019 | 916 | 0.020 |
Why?
| | Critical Illness | 1 | 2019 | 891 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2012 | 79 | 0.020 |
Why?
| | Linear Models | 1 | 2014 | 854 | 0.020 |
Why?
| | Efficiency | 1 | 2012 | 103 | 0.020 |
Why?
| | Health Services | 1 | 2012 | 115 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2011 | 15 | 0.020 |
Why?
| | Hematologic Tests | 1 | 2011 | 21 | 0.020 |
Why?
| | Interferon-beta | 1 | 2011 | 92 | 0.020 |
Why?
| | Employment | 1 | 2012 | 188 | 0.020 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 547 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 920 | 0.020 |
Why?
| | Health Surveys | 1 | 2010 | 518 | 0.020 |
Why?
| | Electrocardiography | 1 | 2011 | 662 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 901 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1519 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2012 | 1173 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3863 | 0.010 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|